TIKOMED
They develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Their products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.
TIKOMED
Social Links:
Industry:
Biotechnology Therapeutics
Founded:
2002-01-01
Address:
Viken, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.tikomed.com
Total Employee:
11+
Status:
Active
Total Funding:
13 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Apple Mobile Web Clips Icon Google Font API WordPress SSL By Default Font Awesome IPv6
Similar Organizations
Cygnal Therapeutics
Cygnal Therapeutics is a biotechnology company
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
Faze Medicines
Faze Medicines is a biotechnology company.
Immunicom
Immunicom is a biotechnology company.
Isarna Therapeutics
Isarna Therapeutics is a biotechnology company.
Laxxon Medical
Laxxon Medical is a biotechnology company.
MolMed
MolMed is a biotechnology company.
Neomorph
Neomorph is a biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
ViroMed
ViroMed is a leading biotechnology company
Current Employees Featured
Founder
Official Site Inspections
http://www.tikomed.com Semrush global rank: 16.28 M Semrush visits lastest month: 1
- Host name: molnet.portsit.se
- IP address: 193.12.211.180
- Location: Lerum Sweden
- Latitude: 57.7705
- Longitude: 12.269
- Timezone: Europe/Stockholm
- Postal: 443 50
More informations about "TikoMed"
The Company - tikomed.com
Before joining TikoMed, Florence was involved in building up the organization and the administrative structure of an international start-up project. Hans Peter Ostler, CEO. Hans …See details»
TikoMed - Crunchbase Company Profile & Funding
Organization. TikoMed . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. TikoMed is a biotechnology company. Viken, Skane ... Alternatives and possible …See details»
TikoMed AB - LinkedIn
TikoMed will be attending Phacilitate's Advanced Therapies Week, January 16-19, taking place at the Miami Beach Convention Center. Reach out to our CEO, Adam Bruce, and learn more about our ...See details»
TIKOMED AB - Develop And Commercialize Innovative Treatments …
TIKOMED AB is a privately owned company based in Viken, Sweden. It is governed by the Laws of the Kingdom of Sweden and was formed in accordance with the Swedish Company Act in …See details»
Tikomed - Overview, News & Similar companies | ZoomInfo.com
Oct 10, 2023 Who is Tikomed. TIKOMED AB is a privately, owned company based in Viken, Sweden. TIKOMED is developing therapeutics for treating acute and degenerative neurologica …See details»
Company Newsroom of TikoMed AB
TIKOMED, a specialty pharma company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB® program) and an infusion …See details»
TikoMed Announces Appointment of Two Independent Directors
Aug 17, 2022 TikoMed AB is a privately-owned biopharmaceutical company based in Viken, Sweden. TikoMed is committed to improving human life by harnessing the medical potential of …See details»
TikoMed - SwedenBIO
TikoMed will then use its board and management network and expertise to. The company has a diversified drug portfolio within the field of pharmaceutical regenerative medicine. The portfolio …See details»
TIKOMED AB Company Profile | Viken, Skåne, Sweden
Find company research, competitor information, contact details & financial data for TIKOMED AB of Viken, Skåne. Get the latest business insights from Dun & Bradstreet.See details»
TikoMed - Company Profile - Tracxn
TikoMed - Developers of regenerative medicine for cell therapies. Raised a total funding of $14.7M over 2 rounds. Founded by Adam Bruce in the year 2002. TikoMed has 543 competitors.See details»
TikoMed AB - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies VIKEN, Sweden, Sept. 13, 2022 /PRNewswire/ -- …See details»
Tikomed Company Profile 2024: Valuation, Funding & Investors
Tikomed was founded in 2002. Where is Tikomed headquartered? Tikomed is headquartered in Viken, Sweden. What is the size of Tikomed? Tikomed has 8 total employees. What industry is …See details»
TikoMed AB - VentureRadar
May 16, 2019 TIKOMED is developing therapeutics for treating acute and degenerative neurological diseases and an immunologically modifying drug for improving outcome in cell …See details»
News & events - Tikomed
Jun 27, 2024 The trial outcomes demonstrated that: TikoMed is now moving forward with planning a phase IIb multi-centre efficacy trial of ILB® Viken, Sweden July 22nd, 2024: …See details»
TikoMed - Contacts, Employees, Board Members, Advisors & Alumni
Organization. TikoMed . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. About. TikoMed has 2 …See details»
Tikomed Company Profile - Office Locations, Competitors ... - Craft
Tikomed is a company that develops treatments for patients with severe and life-threatening conditions. It focuses on neurological and opthalmic diseases as well as regenerative cell …See details»
TikoMed - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Mar 13, 2020: Venture Round - …See details»
TIKOMED Granted Orphan Medicinal Drug Designation for ILB® …
Aug 28, 2020 TIKOMED’s drug candidate, ILB® is a patented Dextran Sulphate which addresses the underlying causes of neurodegeneration in acute and chronic diseases. ILB® …See details»
TikoMed AB reports positive phase II clinical data for the …
May 26, 2022 TikoMed's phase II open label clinical trial conducted at Sahlgrenska University Hospital in Gothenburg, Sweden, evaluated the safety, tolerability and possible efficacy of …See details»